Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Dr. John A. Scarlett M.D.

Chairman of the Board, President & Chief Executive Officer

Ms. Aron  Feingold

Vice President of Investor Relations & Corporate Communications

Ms. Melissa A. Kelly Behrs

Executive Vice President of Business Operations & Chief Alliance Officer

Mr. Edward E. Koval

Executive Vice President & Chief Business Officer

Dr. Faye  Feller M.D.

Executive Vice President & Chief Medical Officer

Ms. Shannon  Odam

Senior Vice President & Chief People Officer

Mr. Scott  Samuels

Executive Vice President, Chief Legal Officer & Corporate Secretary

Mr. Anil  Kapur

Executive Vice President of Corporate Strategy & Chief Commercial Officer

Dr. Andrew J. Grethlein Ph.D.

Executive Vice President & Chief Operating Officer

Ms. Michelle J. Robertson

Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer

Biotechnologie

Geron Corporation

Geron Corporation Structuur van het management

Informatie over het management